InVivoMab anti-mouse CTLA-4 (CD152)

Catalog number: BE0032_100mg
Brand: Bio X Cell
Packing: 100 mg
Other sizes: Other sizes available
Price: € 2715.00
Expected delivery time: 7 days
Quantity:

Product specifications for - InVivoMab anti-mouse CTLA-4 (CD152)

Promotion: 
Promotion: The price displayed is only for academic or non-profit organizations. Please contact our helpdesk for regular prices.
Overview: 
Product group: Antibodies
Category: Primary Antibodies
Application: Flow Cytometry; Neutralisation/Blocking
Species: Mouse
Host: Hamster
Clonality: Monoclonal
Isotype: IgG
Properties: 
Molecular weight: 150 kDa
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352203
Concentration: 2-10 mg/ml
Scientific information: 
Clone ID: UC10-4F10-11
Related products: 
Related products: Recommended Isotype Control(s): InVivoMab polyclonal Armenian hamster IgG (BE0091)
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer (IP0070)
Additional information: 
Synonyms: UC10-4F10-11; BE0032; CTLA4 / CD152; CTLA4; IDDM12; GSE; GRD4; CTLA-4; CELIAC3; CD152; CD; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte protein 4; cytotoxic T-lymphocyte antigen 4; cytotoxic T lymphocyte associated antigen 4 short spliced form; celiac disease 3; CD152 isoform; cytotoxic T-lymphocyte-associated protein 4; BioXCell
Welten SP, Redeker A, Franken KL, et al. The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion. Elife. 2015;4 Read more
Makkouk A, Joshi VB, Lemke CD, et al. Three steps to breaking immune tolerance to lymphoma: a microparticle approach. Cancer Immunol Res. 2015;3(4):389-98. Read more
Pletinckx K, Vaeth M, Schneider T, et al. Immature dendritic cells convert anergic nonregulatory T cells into Foxp3- IL-10+ regulatory T cells by engaging CD28 and CTLA-4. Eur J Immunol. 2015;45(2):480-91. Read more
Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057-69. Read more
Mittal D, Young A, Stannard K, et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014;74(14):3652-8. Read more
Rabenstein H, Behrendt AC, Ellwart JW, et al. Differential kinetics of antigen dependency of CD4+ and CD8+ T cells. J Immunol. 2014;192(8):3507-17. Read more
Honda T, Egen JG, Lämmermann T, Kastenmüller W, Torabi-parizi P, Germain RN. Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity. 2014;40(2):235-247. Read more
Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013;19(20):5626-35. Read more
Hafalla JC, Claser C, Couper KN, et al. The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. PLoS Pathog. 2012;8(2):e1002504. Read more
Haque A, Best SE, Amante FH, et al. CD4+ natural regulatory T cells prevent experimental cerebral malaria via CTLA-4 when expanded in vivo. PLoS Pathog. 2010;6(12):e1001221. Read more